Ansimar

Ansimar is an Italian pharmaceutical company and a subsidiary of ABC Farmaceutici, specializing in the development and commercialization of respiratory therapies. The company is primarily recognized for its flagship product, Ansimar (doxofylline), a methylxanthine derivative used as a bronchodilator for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Doxofylline is distinguished from traditional xanthines like theophylline by its significantly improved safety profile, exhibiting reduced affinity for adenosine receptors and thus fewer cardiac and central nervous system side effects. Ansimar manages the global intellectual property and clinical development of doxofylline, partnering with international distributors to provide respiratory relief to patients worldwide. The company operates out of Ivrea, Italy, leveraging the manufacturing and R&D capabilities of its parent group.